Allergic Asthma, Asthma
Conditions
Keywords
asthma, allergy, Gender, polymorphism
Brief summary
The GINA 2020 guidelines suggest that asthma affects approximately 300 million persons worldwide. Even if there is a specific drug treatment for each stage of disease (From mild to severe) in some patients it is not efficacy and it culd be reated to the gender difference Polymorphisms seems to be involved in asthma (allergic or not) even if no data have been published concerning the role of gender in this clinical manifestation. The aim of this study is to assess whether genetic variations involved in the genes encoding the two key leukotriene enzymes, ALOX5 and LTC4S, and CysLTR1 are implicated in the sex difference of allergic asthma in a well-characterized patient cohort.
Detailed description
The GINA 2020 guidelines suggest that asthma affects approximately 300 million persons worldwide. Even if there is a specific drug treatment for each stage of disease (From mild to severe) in some patients it is not efficacy and it culd be reated to the gender difference Polymorphisms seems to be involved in asthma (allergic or not) even if no data have been published concerning the role of gender in this clinical manifestation. The role of polymorphisms in susceptibility to allergic asthma has been partially investigated but no study has analysed gender subgroups separately, neglecting a their potential predictive role in symptomatological and functional variations in the allergic asthma in both sexes. The aim of this study is to assess whether genetic variations involved in the genes encoding the two key leukotriene enzymes, ALOX5 and LTC4S, and CysLTR1 are implicated in the sex difference of allergic asthma in a well-characterized patient cohort.
Interventions
GENETICgenetic evaluation
A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
OTHERMicroRNA evaluation
Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
Sponsors
Azienda Sanitaria Provinciale Di Catanzaro
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
University of Catanzaro
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* asthma (allergic or not) diagnosed according to Global Initiative for Asthma guidelines (GINA 2020). * signed informed consent
Exclusion criteria
* • infectious diseases * neurodegenerative diseases * autoimmune diseases * neoplasms * progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease) * alcohol consumption (\>3 alcoholic beverages daily) * substanceabuse * inability to give written informed consent * those who will not sign the consent to the processing of personal data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression of SNPs | 1 month | statistically significant difference (P\<0.05) in SNPs expression between male and female |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of MicroRNA | 1 month | statistically significant difference (P\<0.05) in microRNA between male and female |
| SNPs and age | 1 month | statistically significant difference (P\<0.05) in SNPs expression between age \> 12 years and \< 12 years |
Countries
Italy
Outcome results
None listed